Angiotensin Peptides Potentiate SARS-CoV-2 Spike–AXL Binding: Mechanistic Insights and Research Implications

Study Background and Research Question

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, relies on its spike glycoprotein to mediate entry into host cells. While angiotensin-converting enzyme 2 (ACE2) is well-established as the primary viral receptor, alternative host receptors such as neuropilin-1 (NRP1) and AXL have been implicated in facilitating infection, particularly in tissues with low ACE2 expression. The renin–angiotensin system (RAS) is central to cardiovascular regulation, and its peptide hormones may intersect with viral entry pathways. The reference study (Oliveira et al., 2025) investigates whether naturally occurring angiotensin peptides modulate the interaction between the SARS-CoV-2 spike protein and its host cell receptors, with a focus on AXL.

Key Innovation from the Reference Study

The principal innovation of this work lies in demonstrating that angiotensin peptides—including both canonical forms and truncated derivatives—can enhance the binding affinity between the SARS-CoV-2 spike protein and the AXL receptor. Notably, the study distinguishes the effects of different peptide fragments generated through enzymatic processing in the RAS, revealing that specific sequence deletions and amino acid modifications can modulate this enhancement. This finding opens new avenues in understanding how host peptide hormones influence viral tropism and entry efficiency, extending beyond the classical ACE2-centric paradigm of SARS-CoV-2 infection.

Methods and Experimental Design Insights

The authors employed antibody-based binding assays to quantify the interaction between the SARS-CoV-2 spike protein and its receptors (AXL, ACE2, NRP1) in the presence of various angiotensin peptides. Both full-length and truncated forms were tested, including Angiotensin I (1–10), Angiotensin II (1–8), Angiotensin (1–7), Angiotensin IV (3–8), and shorter C- and N-terminal deletions such as Angiotensin 1/2 (5-7), which shares the sequence H2N-Ile-His-Pro-OH. The study also investigated the effects of single amino acid substitutions and post-translational modifications (e.g., tyrosine phosphorylation) on peptide-mediated spike–receptor binding. Quantitative analyses were performed using ELISA-type readouts, enabling precise assessment of relative binding enhancements under different peptide conditions.

Core Findings and Why They Matter

Key results from Oliveira et al., 2025 include:

• Angiotensin II (1–8) induces a two-fold increase in spike–AXL binding, while Angiotensin I (1–10) does not exert this effect.
• Shorter peptide fragments with C-terminal deletions (e.g., Angiotensin (1–7), Angiotensin (1–6)) retain or enhance spike–AXL binding capacity, matching or exceeding Angiotensin II’s effect.
• N-terminal deletions, yielding fragments such as Angiotensin III (2–8), Angiotensin IV (3–8), and Angiotensin 1/2 (5-7), result in even greater potentiation of spike–AXL interaction (up to 2.7-fold with Angiotensin IV).
• Substituting or phosphorylating tyrosine at position 4 of Angiotensin II further augments spike–AXL binding, indicating a structural basis for peptide modulation of viral receptor interaction.
• Angiotensin IV also enhances spike protein binding to ACE2 and NRP1, suggesting broader implications for receptor usage.

These findings suggest that endogenous RAS peptides, especially truncated forms like the H2N-Ile-His-Pro-OH peptide, may actively participate in modulating SARS-CoV-2 host cell attachment, potentially influencing viral dissemination in tissues with variable receptor expression. This mechanistic link may partially explain tissue tropism and disease heterogeneity observed in COVID-19 and positions angiotensin fragments as both mechanistic probes and potential therapeutic targets.

Comparison with Existing Internal Articles

Recent thought-leadership pieces and mechanistic reviews have highlighted the multifaceted role of Angiotensin 1/2 (5-7) in both cardiovascular and viral pathogenesis research. For example, one comprehensive internal review expands on the peptide’s application in dissecting RAS signaling and its emerging relevance in COVID-19 models, providing experimental validation for its use as a mechanistic probe. Another analysis directly addresses how high-purity Angiotensin 1/2 (5-7) supports next-generation studies of both blood pressure regulation and SARS-CoV-2 spike protein interactions. These articles converge with findings from the reference study by affirming the peptide’s dual relevance in cardiovascular and infectious disease research, but the peer-reviewed data now offer a quantitative, receptor-specific mechanism for these cross-domain effects.

Limitations and Transferability

While the referenced study robustly demonstrates peptide-mediated enhancement of spike–AXL binding in vitro, several limitations warrant consideration. The assays were conducted under controlled laboratory conditions using recombinant proteins and may not fully recapitulate the complexity of in vivo environments. The concentration ranges employed may differ from physiological peptide levels encountered during disease states. Furthermore, although increased spike–receptor binding suggests a potential mechanism for heightened infectivity or tissue tropism, the study does not directly assess viral entry or replication in cellular or animal models. As such, translational implications for therapeutic targeting or disease modulation require further validation in relevant biological systems. The transferability of these findings to clinical contexts remains an open question.

Why this cross-domain matters, maturity, and limitations

The intersection of renin-angiotensin system research with viral pathogenesis is of high interest, given the dual role of angiotensin peptides in blood pressure regulation and as biochemical modulators of viral entry. As shown in the cited work, truncated angiotensin fragments such as H2N-Ile-His-Pro-OH hold unique value for probing both cardiovascular mechanisms and SARS-CoV-2 receptor interactions. However, the mechanistic bridge remains exploratory; clinical utility and disease relevance will depend on further validation beyond in vitro binding enhancement.

Research Support Resources

Researchers aiming to replicate or extend these workflows can source high-purity Angiotensin 1/2 (5-7) (SKU A1049) from APExBIO, which provides the peptide with confirmed purity and solubility for advanced biochemical assays. Detailed mechanistic discussions and translational perspectives are available in complementary internal articles. For experimental design, the following parameters are recommended:

Protocol Parameters

• Peptide solubility: Angiotensin 1/2 (5-7) is soluble at ≥36.5 mg/mL in DMSO, ≥50 mg/mL in ethanol, and ≥50 mg/mL in water; prepare fresh solutions shortly before use to ensure activity.
• Storage conditions: Store the peptide as a solid at -20°C; avoid repeated freeze-thaw cycles and use reconstituted solutions only for short-term experiments.
• Binding assay concentration: Literature-based assays often use 1–10 μM concentrations for peptide-mediated receptor binding studies; titrate as needed for specific assay sensitivity and dynamic range.
• Receptor binding workflow: Incubate angiotensin peptides with target receptor proteins in ELISA or surface plasmon resonance setups to quantify binding modulation, referencing the methods in the reference study.

In summary, the convergence of peptide hormone research with viral entry studies provides a fertile ground for understanding both cardiovascular and infectious disease mechanisms. Angiotensin 1/2 (5-7) serves as a precise tool for interrogating these processes, backed by both internal resources and peer-reviewed mechanistic evidence.